Fineotex Chem Q1 FY27 Results (NSE: FCL)
Signal: Margin pressure
The read
Revenue growth inflected sharply upward (+164% YoY) on the back of the CrudeChem acquisition and domestic demand, but EBITDA margin contracted 500bps YoY to 15.7% as higher employee/other costs from integration and scaling outpaced gross margin gains. PAT grew 93% YoY, slightly below revenue growth, reflecting the margin drag. The company successfully passed on raw material costs, preserving gross margin expansion, which is a key positive.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹386.72 Cr | 164.48% | 19.66% |
| Net profit | ₹48.21 Cr | 92.67% | |
| EBIT margin | 15.70% |
P&L walk
Revenue growth is driven by the acquisition of CrudeChem and strong domestic demand. Gross margin expanded 290bps YoY to 35.42% on pricing actions passing higher raw material costs, but EBITDA margin contracted 500bps YoY to 15.70% due to higher opex (employee/other costs) from scaling and integration. PAT grew 93% YoY, slightly lagging revenue growth because of margin compression.
Key positives
- Revenue surged 164.48% YoY to ₹386.7 Cr, powered by CrudeChem acquisition and strong core demand.
- Gross margin expanded 290bps YoY to 35.42%, indicating pricing power despite input cost inflation.
- PAT up 92.67% YoY, keeping pace with revenue growth.
- Capacity expansion commissioned at Texas facility, increasing total capacity to ~1,48,000 MTPA.
- ROIC at 33.06% and ROCE at 25.56% remain healthy.
Key concerns
- EBITDA margin contracted 500bps YoY to 15.70% due to higher employee and other costs from integration and scaling.
- EBITDA margin also declined 200bps QoQ, continuing the contraction trend observed in recent quarters.
- EPS not disclosed; equity dilution impact cannot be assessed.
Research and educational content only. Not investment advice.